News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
737,682 Results
Type
Article (43652)
Company Profile (473)
Press Release (693545)
Multimedia
Podcasts (122)
Webinars (20)
Section
Business (209305)
Career Advice (2038)
Deals (36150)
Drug Delivery (119)
Drug Development (83957)
Employer Resources (174)
FDA (16683)
Job Trends (15185)
News (354121)
Policy (33274)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2655)
Accelerated approval (34)
Adcomms (28)
Allergies (141)
Alliances (51111)
ALS (176)
Alzheimer's disease (1718)
Antibody-drug conjugate (ADC) (325)
Approvals (16919)
Artificial intelligence (533)
Autoimmune disease (149)
Automation (37)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (191)
Biotechnology (331)
Bladder cancer (162)
Brain cancer (59)
Breast cancer (645)
Cancer (4891)
Cardiovascular disease (414)
Career advice (1723)
Career pathing (37)
CAR-T (287)
CDC (46)
Celiac Disease (2)
Cell therapy (767)
Cervical cancer (36)
Clinical research (71375)
Collaboration (1768)
Company closure (4)
Compensation (1160)
Complete response letters (62)
COVID-19 (2769)
CRISPR (96)
C-suite (854)
Cystic fibrosis (152)
Data (6251)
Decentralized trials (2)
Denatured (39)
Depression (141)
Diabetes (500)
Diagnostics (6733)
Digital health (45)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (258)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (239)
Earnings (91321)
Editorial (59)
Employer branding (21)
Employer resources (152)
Events (120921)
Executive appointments (993)
FDA (19803)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (10)
Frontotemporal dementia (24)
Funding (1514)
Gene editing (211)
Generative AI (44)
Gene therapy (635)
GLP-1 (1006)
Government (4752)
Grass and pollen (6)
Guidances (384)
Healthcare (19201)
HIV (57)
Huntington's disease (46)
IgA nephropathy (85)
Immunology and inflammation (270)
Immuno-oncology (58)
Indications (104)
Infectious disease (3033)
Inflammatory bowel disease (196)
Inflation Reduction Act (17)
Influenza (113)
Intellectual property (247)
Interviews (315)
IPO (16929)
IRA (52)
Job creations (3712)
Job search strategy (1439)
JPM (65)
Kidney cancer (15)
Labor market (83)
Layoffs (580)
Leadership (32)
Legal (8025)
Liver cancer (93)
Longevity (14)
Lung cancer (658)
Lymphoma (377)
Machine learning (43)
Management (59)
Manufacturing (797)
MASH (169)
Medical device (13907)
Medtech (13959)
Mergers & acquisitions (20288)
Metabolic disorders (1305)
Multiple sclerosis (160)
NASH (19)
Neurodegenerative disease (332)
Neuropsychiatric disorders (95)
Neuroscience (2991)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4579)
Now hiring (65)
Obesity (624)
Opinion (280)
Ovarian cancer (166)
Pain (202)
Pancreatic cancer (229)
Parkinson's disease (294)
Partnered (34)
Patents (491)
Patient recruitment (484)
Peanut (56)
People (60258)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22452)
Phase 2 (31468)
Phase 3 (23268)
Pipeline (5146)
Policy (294)
Postmarket research (2602)
Preclinical (9600)
Press Release (67)
Prostate cancer (243)
Psychedelics (55)
Radiopharmaceuticals (296)
Rare diseases (875)
Real estate (6063)
Recruiting (70)
Regulatory (24941)
Reports (51)
Research institute (2482)
Resumes & cover letters (353)
Rett syndrome (27)
RNA editing (21)
RSV (76)
Schizophrenia (154)
Series A (253)
Series B (196)
Service/supplier (11)
Sickle cell disease (103)
Special edition (26)
Spinal muscular atrophy (162)
Sponsored (42)
Startups (3803)
State (2)
Stomach cancer (18)
Supply chain (106)
Tariffs (85)
The Weekly (81)
Vaccines (1014)
Venture capital (93)
Weight loss (405)
Women's health (89)
Worklife (19)
Date
Today (16)
Last 7 days (610)
Last 30 days (2302)
Last 365 days (30675)
2026 (2907)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (89)
Alaska (7)
Arizona (314)
Arkansas (14)
Asia (40668)
Australia (6758)
California (11380)
Canada (3274)
China (1125)
Colorado (481)
Connecticut (489)
Delaware (335)
Europe (89127)
Florida (1671)
Georgia (357)
Hawaii (3)
Idaho (61)
Illinois (876)
India (63)
Indiana (519)
Iowa (24)
Japan (425)
Kansas (129)
Kentucky (40)
Louisiana (27)
Maine (72)
Maryland (1395)
Massachusetts (8273)
Michigan (322)
Minnesota (634)
Mississippi (5)
Missouri (127)
Montana (33)
Nebraska (28)
Nevada (121)
New Hampshire (83)
New Jersey (3029)
New Mexico (31)
New York (2980)
North Carolina (1517)
North Dakota (9)
Northern California (5522)
Ohio (334)
Oklahoma (21)
Oregon (45)
Pennsylvania (2281)
Puerto Rico (22)
Rhode Island (48)
South America (1121)
South Carolina (65)
South Dakota (1)
Southern California (4412)
Tennessee (173)
Texas (1748)
United States (40482)
Utah (339)
Vermont (1)
Virginia (264)
Washington D.C. (82)
Washington State (951)
West Virginia (4)
Wisconsin (112)
Wyoming (2)
737,682 Results for "adcentrx therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
U.S. FDA Grants Orphan Drug Designation to Adcentrx Therapeutics’ ADRX-0405 STEAP1 ADC for Gastric Cancer
July 8, 2025
·
3 min read
Business
Adcentrx Therapeutics Appoints Meng Jiang as Chief Financial Officer
Adcentrx Therapeutics (“Adcentrx”), a biotechnology company revolutionizing Antibody-Drug Conjugate (ADC) therapeutics for cancer and other life-threatening diseases, announced today the appointment of Meng Jiang as Chief Financial Officer (CFO).
April 8, 2024
·
2 min read
Press Releases
Adcentrx Therapeutics to Present First Clinical Data for ADRX-0706 Nectin-4 ADC at ASCO 2025
April 23, 2025
·
4 min read
Press Releases
Adcentrx Therapeutics Granted Fast Track Designation for ADRX-0706 Nectin-4 ADC for the Treatment of Advanced Cervical Cancer
May 7, 2025
·
4 min read
Drug Development
Adcentrx Therapeutics Announces China NMPA Grants IND Clearance for ADRX-0706, a Novel Nectin-4 ADC for the Treatment of Advanced Solid Tumors
Adcentrx Therapeutics (“Adcentrx”) announced today that China National Medical Products Administration (NMPA) has cleared Adcentrx’s Investigational New Drug (IND) application for ADRX-0706 which enables the company to include China-based clinical centers in the ongoing Phase 1a/1b study for the treatment of select advanced solid tumors.
May 6, 2024
·
3 min read
Press Releases
Adcentrx Therapeutics to Showcase Novel STEAP1 and NaPi2b ADCs with Oral and Poster Presentations at AACR 2025
March 26, 2025
·
4 min read
Biotech Beach
Adcentrx Therapeutics to Present Preclinical Data for Nectin-4 ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
Adcentrx Therapeutics (“Adcentrx”) today announced that preclinical data for ADRX-0706 will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, CA.
April 1, 2024
·
3 min read
Business
Adcentrx Therapeutics Announces Formation of Scientific Advisory Board
September 10, 2024
·
4 min read
Press Releases
Adcentrx Therapeutics Doses First Patient in Phase 1b Expansion Cohorts with ADRX-0706 Nectin-4 ADC
December 3, 2024
·
3 min read
Biotech Beach
Adcentrx Announces Extension of Series A+ Financing to $51 Million
Adcentrx Therapeutics, a biotechnology company dedicated to revolutionizing Antibody-Drug Conjugate therapeutics for cancer and other life-threatening diseases, announced the extension of its Series A+ financing.
December 5, 2023
·
3 min read
1 of 73,769
Next
